-
A shift has occurred in recent years from viewing menopause as "a natural life event" experienced by women to "a condition that requires medical management."
-
Tiotropium for uncontrolled asthma, sibutramine pulled from market, incidence and mortality data from WHI, FDA Actions.
-
A murine model was employed to assess the effects of chronic stress on metastatic breast cancer spread. The researchers used a variety of tools to investigate the neuroendocrine, molecular, and cellular effects of chronic stress in this setting. Their findings suggest that chronic stress induces a significant increase in the extent of cancer spread through the activity of the sympathetic nervous system. The findings open numerous research questions yet to be answered, as well as great therapeutic possibilities.
-
It has long been assumed that acetaminophen, the common analgesic agent, is relatively safe for people with known coronary artery disease, in contrast to NSAIDs and COX-2 inhibitors. But assumptions can be dangerous, and this small study suggests that acetaminophen use may have similar risks associated with it, specifically increases in blood pressure.
-
-
The authors enrolled women desiring postpartum use of a levonorgestrel-releasing intrauterine system in a randomized trial to determine whether use of the device would be higher when insertion occurred immediately postpartum rather than delaying placement to the standard postpartum visit.
-
In this issue: Rivaroxaban may be dabigatran's first competitor; a new way to measure non-adherence to medication therapy; FDA Actions.
-
-
The rate of sepsis with group b streptococcus (gbs) in neonates of colonized mothers is now less than 1%.
-
The authors randomized women with objectively validated heavy menstrual bleeding (mean menstrual blood loss [MBL] of 80 mL or more per cycle, confirmed using the alkaline hematin methodology during two pretreatment cycles) to treatment with oral tranexamic acid 3.9 g/d or placebo for up to 5 days per cycle for 6 menstrual cycles.
